What is DYAI's market cap?

$13.63M, based on the Nov 5 close of $0.34.

Does Dyadic International pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DYAI is sold short?

194.7K shares, 0.7% of float, as of Oct 15, 2026.

What sector is DYAI in?

Healthcare, in the Biotechnology industry.

NASDAQ · DYAIHealthcareBiotechnology

Dyadic International, Inc. (DYAI)

$0.3401−7.25%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$0.35▼ 66.48% in range

Nov 4, 2025Low $0.35 · High $1.47Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Dyadic International closed at $0.34 on Nov 5, down 7.25%, within 0.0% of its 52-week closing low. Volume of 81.6K shares was 0.89× its 20-day average (close to normal).

Split-adjusted performance: -25.5% over one month, -54.3% over six months, -67.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $961.14K, down 0.6% from a year earlier, with a net margin of -221.0%.

Short interest was 194.7K shares at the Oct 15 settlement, up 8.8% from the prior report (0.7% of float, 1.7 days to cover).

Market cap$13.6M40.1M shares

Revenue · quarter$961.1K−0.6% YoY

Diluted EPS$-0.06—

P/E · TTM—P/S 3.6×

Net margin-221.0%Gross -2.4%

Dividend yieldNone

52-week range0.34 – 1.47−76.9% from high

Volume81.6K0.89× 20-day avg

Volatility · 60d70.4%Annualised

Short % of float0.7%1.7 days to cover

Net cash-$1.9MCash $3.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.8%1M −25.5%3M −66.0%6M −54.3%YTD −63.8%1Y −67.6%3Y −79.0%5Y −92.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum25

Revenue growth38

Net margin51

Value (low P/E)—

Size12

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →

Shares short194.7K+8.8% vs prior

Days to cover1.7Settled Oct 15

% of float0.7%

Short vol. 10d28.2%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DYAIDyadic International	$0.3401	−7.25%	−54.3%	−0.6%	−221.0%	—	$13.6M
BCDABioCardia	$0.8900	−2.53%	−18.3%	—	—	—	$13.5M	Compare
TCRXTScan Therapeutics	$0.1818	−13.43%	−85.0%	−65.8%	−2888.6%	—	$12.3M	Compare
ATYRaTyr Pharma	$6.03	−2.43%	−83.6%	—	—	—	$15.1M	Compare
ABOSAcumen Pharmaceuticals	$0.2138	−1.16%	−91.3%	—	—	—	$15.5M	Compare
SCLXScilex Holding	$1.70	−7.10%	−78.9%	−22.8%	−1501.3%	—	$12.0M	Compare
JSPRJasper Therapeutics	$0.4692	−8.20%	−48.3%	—	—	—	$15.6M	Compare
PLURPluri	$1.19	−3.26%	−64.4%	−15.8%	−1755.2%	—	$16.1M	Compare
PASGPassage Bio	$3.46	−1.42%	−15.2%	—	—	—	$11.1M	Compare

News about Dyadic International

All news →

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme ProgramGlobeNewswire Inc. · Jul 16, 2026▲ Positive Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ETGlobeNewswire Inc. · May 21, 2026▲ Positive

Quick answers

What does Dyadic International do?: Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications.
What is DYAI's market cap?: $13.63M, based on the Nov 5 close of $0.34.
Does Dyadic International pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DYAI is sold short?: 194.7K shares, 0.7% of float, as of Oct 15, 2026.
What sector is DYAI in?: Healthcare, in the Biotechnology industry.

About Dyadic International

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

HQ: Jupiter, FL5 employeesListed Nov 5, 2004dyadic.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology